Endonovo Announces First Commercial Sales for SofPulse Wearable Electroceutical for Post-Operative Pain and Edema
January 22 2018 - 07:27AM
InvestorsHub NewsWire
Seeking Distribution
Partners in Europe for CE-Marked Electroceutical™ Device for
Promotion of Wound Healing, Reduction of Pain and Post-Operative
Edema
Los Angeles, CA -- January 22, 2018 -- InvestorsHub
NewsWire -- Endonovo Therapeutics, Inc. (OTCQB: ENDV)
("Endonovo" or the "Company"), a commercial-stage developer of
non-invasive wearable Electroceutical™ devices, today announced the
first commercial sales of SofPulse™, its non-invasive,
wearable Electroceutical™ device. SofPulse™ is the Company's
FDA-Cleared Electroceutical™ System for the palliative treatment of
post-operative pain and edema in superficial soft tissues.
Furthermore, the Company announced it is seeking distribution
partners in Europe for SofPulse™, which is CE-Marked for the
promotion of wound healing, reduction of pain and post-operative
edema.
"We are very excited to begin sales of SofPulse™ under Endonovo
management," said Endonovo CEO, Alan Collier. "Our wearable
Electroceutical™ was FDA-Cleared in 2008, but no significant effort
to commercialize this revolutionary technology was ever undertaken.
SofPulse™ has shown 80% acceleration in pain relief in breast
augmentation patients and 2-fold less narcotics use in breast
reconstruction patients."
"As we battle an opioid epidemic we must look for novel ways to
relieve pain for people suffering from chronic pain, as well as
preventing people undergoing surgical procedures from becoming
dependent on narcotics. We believe our wearable Electroceutical™
can drastically reduce the need for pain medication use and improve
the lives of millions of people suffering from pain."
"Unlike many of our competitors using electrical stimulation,
some of whom have signed agreements with large device and
pharmaceutical companies, our devices don't simply mask the pain,
they address the underlying issue causing the pain, which is
inflammation," stated Mr. Collier.
"We are actively seeking to establish channel partnerships with
global device and healthcare companies to commercialize our
wearable Electroceuticals™ in Europe," concluded Mr. Collier.
About SofPulse™ Electroceutical™ System
SofPulse™ is an easy-to-place, non-invasive device that
delivers targeted MicroCurrent Therapy (tMCT) to enhance
post-surgical recovery, naturally. tMCT is an innovative process
that uses proprietary technology to reduce pain and swelling. The
therapy is non-invasive and non-pharmacologic, with no known side
effects and no potential for overdose or dependency. SofPulse™ has
been used effectively and studied extensively in soft tissue
post-operative management. The low levels of microcurrent are
completely safe and in fact, are 1000 times lower than those
emitted by a mobile phone. SofPulse™ is manufactured, marketed and
distributed through ADM Tronics Unlimited, Inc.
The Company's wearable Electroceuticals™ have been evaluated in
5 randomized, controlled clinical trials and have demonstrated
significant reductions in pain, post-surgical edema and use of pain
medication.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of
non-invasive wearable Electroceuticals™. The Company's current
portfolio of commercial and clinical-stage wearable
Electroceuticals™ addresses wound healing, pain, post-surgical
edema and Central Nervous System (CNS) Disorders, including
traumatic brain injury (TBI), acute concussions, post-concussion
syndrome and multiple sclerosis. The Company's non-invasive
Electroceutical™ device using pulsed short-wave radiofrequency at
27.12 MHz has been FDA-Cleared and CE Marked for the palliative
treatment of soft tissue injuries and post-operative pain and
edema, and has CMS National Coverage for the treatment of chronic
wounds. The Company's current portfolio of pre-clinical stage
Electroceuticals™ addresses chronic kidney disease, liver disease,
cardiovascular and peripheral artery disease. The Company's
non-invasive, wearable Electroceuticals™ work by restoring key
electrochemical processes that initiate anti-inflammatory and
growth factor cascades necessary for healing to occur.
Safe Harbor Statement
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained
in this press release including words such as "anticipate,"
"believe," "plan," "estimate," "expect," "intend," and other
similar expressions of opinion, constitute forward-looking
statements. Any such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from any future results described within the forward-looking
statements. Risk factors that could contribute to such differences
include those matters more fully disclosed in the Company's reports
filed with the Securities and Exchange Commission. The
forward-looking information provided herein represents the
Company's estimates as of the date of the press release, and
subsequent events and developments may cause the Company's
estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied
upon as representing the Company's estimates of its future
financial performance as of any date subsequent to the date of this
press release.
Investor Relations Contact:Endonovo Therapeutics, Inc. Mr. Steven BarnesSenior Vice President of Investor Relations (800) 701-1223, Ext. 108S barnes@endonovo.com www.endonovo.com Source: Endonovo Therapeutics, Inc.Investors: Sign Up for Email Alerts on Endonovo